Please login to the form below

Not currently logged in
Email:
Password:

lorlatinib

This page shows the latest lorlatinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s flat sales focus investor attention on M&A

Pfizer’s flat sales focus investor attention on M&A

Among the highlights cited by Read on the call were oncology drugs talazoparib - a PARP inhibitor due for filing shortly for breast cancer - along with ALK/ROS1 inhibitor lorlatinib and EGFR

Latest news

  • Pfizer files third-gen ALK inhibitor for lung cancer Pfizer files third-gen ALK inhibitor for lung cancer

    Pfizer files third-gen ALK inhibitor for lung cancer. The US FDA is set to make a decision on lorlatinib later this year. ... Lorlatinib was developed by Pfizer scientists with the specific goal of overcoming resistance to first- and second-generation ALK

  • Archive listing

    The US FDA is set to make a decision on lorlatinib later this year. .

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics